Semin intervent Radiol 2017; 34(02): 132-139
DOI: 10.1055/s-0037-1601852
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA

Making the Case: Intra-arterial Therapy for Less Common Metastases

Andrew C. Gordon
1   Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, Illinois
,
Omar M. Uddin
1   Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, Illinois
,
Ahsun Riaz
1   Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, Illinois
,
Riad Salem
1   Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, Illinois
2   Division of Hematology and Oncology, Department of Medicine, Northwestern University, Chicago, Illinois
3   Division of Transplant Surgery, Department of Surgery, Northwestern University, Chicago, Illinois
,
Robert J. Lewandowski
1   Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, Illinois
2   Division of Hematology and Oncology, Department of Medicine, Northwestern University, Chicago, Illinois
3   Division of Transplant Surgery, Department of Surgery, Northwestern University, Chicago, Illinois
› Author Affiliations
Further Information

Publication History

Publication Date:
01 June 2017 (online)

Abstract

Intra-arterial therapies have high antitumor activity for both primary and secondary hepatic malignancies. Selective infusions allow increased delivery of cytoreductive therapy to the tumor bed while sparing the normal hepatic parenchyma. These therapies are now often applied in the outpatient setting or with short overnight hospital stays and have a growing role in the treatment of liver-dominant disease from metastatic colorectal cancer and from neuroendocrine tumors. Less commonly, intra-arterial therapies are applied to treat secondary hepatic malignancies from breast cancer, melanoma, pancreatic adenocarcinoma, and soft-tissue sarcomas. The available data are limited and generally retrospective observational cohort series of single institutions. The purpose of this article is to summarize the recent literature on outcomes for intra-arterial therapy in nonsurgical patients. Multi-institutional registries and prospective data are greatly needed, as intra-arterial therapies are increasingly applied in these patients to stop progression of chemorefractory tumors.

 
  • References

  • 1 Centeno BA. Pathology of liver metastases. Cancer Contr 2006; 13 (01) 13-26
  • 2 Goodman ZD. Neoplasms of the liver. Mod Pathol 2007; 20 (Suppl. 01) S49-S60
  • 3 Sato KT, Lewandowski RJ, Mulcahy MF. , et al. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival. Radiology 2008; 247 (02) 507-515
  • 4 Lewandowski RJ, Geschwind JF, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiology 2011; 259 (03) 641-657
  • 5 Hickey RM, Lewandowski RJ, Salem R. Rationale of transcatheter intra-arterial therapies of hepatic cancers. Hepatic Oncology 2014; 1 (03) 285-291
  • 6 Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 2006; 17 (08) 1251-1278
  • 7 Lewandowski RJ, Sato KT, Atassi B. , et al. Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol 2007; 30 (04) 571-592
  • 8 Zinser JW, Hortobagyi GN, Buzdar AU, Smith TL, Fraschini G. Clinical course of breast cancer patients with liver metastases. J Clin Oncol 1987; 5 (05) 773-782
  • 9 Atalay G, Biganzoli L, Renard F. , et al; EORTC Breast Cancer and Early Clinical Studies Groups. Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials. Eur J Cancer 2003; 39 (17) 2439-2449
  • 10 Cummings MC, Simpson PT, Reid LE. , et al. Metastatic progression of breast cancer: insights from 50 years of autopsies. J Pathol 2014; 232 (01) 23-31
  • 11 Pagani O, Senkus E, Wood W. , et al; ESO-MBC Task Force. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?. J Natl Cancer Inst 2010; 102 (07) 456-463
  • 12 Hickey R, Mulcahy MF, Lewandowski RJ. , et al. Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization. Int J Radiat Oncol Biol Phys 2014; 88 (05) 1025-1031
  • 13 Gordon AC, Salem R, Lewandowski RJ. Yttrium-90 radioembolization for breast cancer liver metastases. J Vasc Interv Radiol 2016; 27 (09) 1316-1319
  • 14 Ang C, Jhaveri K, Patel D, Gewirtz A, Seidman A, Kemeny N. Hepatic arterial infusion and systemic chemotherapy for breast cancer liver metastases. Breast J 2013; 19 (01) 96-99
  • 15 Arai Y, Sone Y, Inaba Y, Ariyoshi Y, Kido C. Hepatic arterial infusion chemotherapy for liver metastases from breast cancer. Cancer Chemother Pharmacol 1994; 33 (1, Suppl): S142-S144
  • 16 Cho SW, Kitisin K, Buck D. , et al. Transcatheter arterial chemoembolization is a feasible palliative locoregional therapy for breast cancer liver metastases. Int J Surg Oncol 2010; 2010: 251621
  • 17 Vogl TJ, Naguib NN, Nour-Eldin NE. , et al. Repeated chemoembolization followed by laser-induced thermotherapy for liver metastasis of breast cancer. AJR Am J Roentgenol 2011; 196 (01) W66-72
  • 18 Eichler K, Jakobi S, Gruber-Rouh T, Hammerstingl R, Vogl TJ, Zangos S. Transarterial chemoembolisation (TACE) with gemcitabine: phase II study in patients with liver metastases of breast cancer. Eur J Radiol 2013; 82 (12) e816-e822
  • 19 Martin RCG, Joshi J, Robbins K. , et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol 2011; 18 (01) 192-198
  • 20 Haug AR, Tiega Donfack BP, Trumm C. , et al. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. J Nucl Med 2012; 53 (03) 371-377
  • 21 Cianni R, Pelle G, Notarianni E. , et al. Radioembolisation with (90)Y-labelled resin microspheres in the treatment of liver metastasis from breast cancer. Eur Radiol 2013; 23 (01) 182-189
  • 22 Saxena A, Kapoor J, Meteling B, Morris DL, Bester L. Yttrium-90 radioembolization for unresectable, chemoresistant breast cancer liver metastases: a large single-center experience of 40 patients. Ann Surg Oncol 2014; 21 (04) 1296-1303
  • 23 Gordon AC, Gradishar WJ, Kaklamani VG. , et al. Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy. J Vasc Interv Radiol 2014; 25 (10) 1523-1532 , 1532.e1–1532.e2
  • 24 Fendler WP, Lechner H, Todica A. , et al. Safety, efficacy, and prognostic factors after radioembolization of hepatic metastases from breast cancer: a large single-center experience in 81 patients. J Nucl Med 2016; 57 (04) 517-523
  • 25 Pieper CC, Meyer C, Wilhelm KE. , et al. Yttrium-90 radioembolization of advanced, unresectable breast cancer liver metastases-a single-center experience. J Vasc Interv Radiol 2016; 27 (09) 1305-1315
  • 26 Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003; 44 (11) 4651-4659
  • 27 Buder K, Gesierich A, Gelbrich G, Goebeler M. Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives. Cancer Med 2013; 2 (05) 674-686
  • 28 Agarwala SS, Eggermont AM, O'Day S, Zager JS. Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options. Cancer 2014; 120 (06) 781-789
  • 29 Leyvraz S, Piperno-Neumann S, Suciu S. , et al. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial. Ann Oncol 2014; 25 (03) 742-746
  • 30 Gonsalves CF, Eschelman DJ, Thornburg B, Frangos A, Sato T. Uveal melanoma metastatic to the liver: chemoembolization with 1,3-Bis-(2-Chloroethyl)-1-nitrosourea. AJR Am J Roentgenol 2015; 205 (02) 429-433
  • 31 Valsecchi ME, Terai M, Eschelman DJ. , et al. Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases. J Vasc Interv Radiol 2015; 26 (04) 523-32.e2
  • 32 Carling U, Dorenberg EJ, Haugvik SP. , et al. Transarterial chemoembolization of liver metastases from uveal melanoma using irinotecan-loaded beads: treatment response and complications. Cardiovasc Intervent Radiol 2015; 38 (06) 1532-1541
  • 33 Valpione S, Aliberti C, Parrozzani R. , et al. A retrospective analysis of 141 patients with liver metastases from uveal melanoma: a two-cohort study comparing transarterial chemoembolization with CPT-11 charged microbeads and historical treatments. Melanoma Res 2015; 25 (02) 164-168
  • 34 Gonsalves CF, Eschelman DJ, Sullivan KL, Anne PR, Doyle L, Sato T. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. AJR Am J Roentgenol 2011; 196 (02) 468-473
  • 35 Memon K, Kuzel TM, Vouche M, Atassi R, Lewandowski RJ, Salem R. Hepatic yttrium-90 radioembolization for metastatic melanoma: a single-center experience. Melanoma Res 2014; 24 (03) 244-251
  • 36 Klingenstein A, Haug AR, Zech CJ, Schaller UC. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients. Cardiovasc Intervent Radiol 2013; 36 (01) 158-165
  • 37 Von Hoff DD, Ervin T, Arena FP. , et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369 (18) 1691-1703
  • 38 Conroy T, Desseigne F, Ychou M. , et al; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364 (19) 1817-1825
  • 39 Pelzer U, Schwaner I, Stieler J. , et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 2011; 47 (11) 1676-1681
  • 40 Danet IM, Semelka RC, Nagase LL, Woosely JT, Leonardou P, Armao D. Liver metastases from pancreatic adenocarcinoma: MR imaging characteristics. J Magn Reson Imaging 2003; 18 (02) 181-188
  • 41 Sho M, Tanaka T, Yamada T. , et al. Novel postoperative adjuvant strategy prevents early hepatic recurrence after resection of pancreatic cancer. J Hepatobiliary Pancreat Sci 2011; 18 (02) 235-239 , discussion 239–240
  • 42 Hashimoto A, Tanaka T, Sho M. , et al. Adjuvant hepatic arterial infusion chemotherapy after resection for pancreatic cancer using coaxial catheter-port system compared with conventional system. Cardiovasc Intervent Radiol 2016; 39 (06) 831-839
  • 43 Hashimoto A, Nishiofuku H, Tanaka T. , et al. Safety and optimal management of hepatic arterial infusion chemotherapy after pancreatectomy for pancreatobiliary cancer. AJR Am J Roentgenol 2012; 198 (04) 923-930
  • 44 Tajima H, Kitagawa H, Tsukada T. , et al. Hepatic arterial infusion chemotherapy with gemcitabine and 5-fluorouracil or oral S-1 improves the prognosis of patients with postoperative liver metastases from pancreatic cancer. Mol Clin Oncol 2013; 1 (05) 869-874
  • 45 Kim JH, Choi EK, Yoon HK, Ko GY, Sung KB, Gwon DI. Transcatheter arterial chemoembolization for hepatic recurrence after curative resection of pancreatic adenocarcinoma. Gut Liver 2010; 4 (03) 384-388
  • 46 Azizi A, Naguib NN, Mbalisike E, Farshid P, Emami AH, Vogl TJ. Liver metastases of pancreatic cancer: role of repetitive transarterial chemoembolization (TACE) on tumor response and survival. Pancreas 2011; 40 (08) 1271-1275
  • 47 Kotoyan R, Metzger T, Tatum C, Robbins K, Martin II RCG. Hepatic arterial therapy with drug-eluting beads in the management of metastatic pancreatic carcinoma to the liver: a multi-institutional registry. J Oncol 2012; 2012: 168303
  • 48 Cao C, Yan TD, Morris DL, Bester L. Radioembolization with yttrium-90 microspheres for pancreatic cancer liver metastases: results from a pilot study. Tumori 2010; 96 (06) 955-958
  • 49 Gibbs P, Do C, Lipton L. , et al. Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma. BMC Cancer 2015; 15: 802
  • 50 Kim AY, Unger K, Wang H, Pishvaian MJ. Incorporating Yttrium-90 trans-arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcinoma: a single center experience. BMC Cancer 2016; 16: 492
  • 51 Michl M, Lehner S, Paprottka PM. , et al. Use of PERCIST for prediction of progression-free and overall survival after radioembolization for liver metastases from pancreatic cancer. J Nucl Med 2016; 57 (03) 355-360
  • 52 Blay JY, Shen L, Kang YK. , et al. Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. Lancet Oncol 2015; 16 (05) 550-560
  • 53 Maluccio MA, Covey AM, Schubert J. , et al. Treatment of metastatic sarcoma to the liver with bland embolization. Cancer 2006; 107 (07) 1617-1623
  • 54 Takaki H, Litchman T, Covey A. , et al. Hepatic artery embolization for liver metastasis of gastrointestinal stromal tumor following imatinib and sunitinib therapy. J Gastrointest Cancer 2014; 45 (04) 494-499
  • 55 Chapiro J, Duran R, Lin M. , et al. Transarterial chemoembolization in soft-tissue sarcoma metastases to the liver - the use of imaging biomarkers as predictors of patient survival. Eur J Radiol 2015; 84 (03) 424-430
  • 56 Rajan DK, Soulen MC, Clark TW. , et al. Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol chemoembolization. J Vasc Interv Radiol 2001; 12 (02) 187-193
  • 57 Transue DL, Hackworth J, Johnson MS, Habib A. Multi-institutional experience treating metastatic soft tissue sarcomas using yttrium-90 microspheres. J Vasc Interv Radiol 2015; 26 (02) S133